Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Phase 1 Completed 23 enrolled Tanabe Pharma America, Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

An Open-label, Single-center, Parallel-group Study to Assess Pharmacokinetics, Safety, and Tolerability of a Single Dose of MT-7117 in Subjects with Normal and Impaired Hepatic Function

Timeline

Start: 2019-08-01
Primary completion: 2021-02-16
Completion: 2021-02-16

Publications

Ogasawara A, Ide R, Inoue S, Teng R, Kawaguchi A. Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT-7117), an Oral Melanocortin-1 Receptor Agonist. Clin Pharmacol Drug Dev. 2024 Jul;13(7):729-738. doi: 10.1002/cpdd.1413. Epub 2024 May 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dersimelagon	Small molecule	100 mg	Oral

Indications

No indication recorded.